Quoin Pharmaceuticals Management
Management criteria checks 3/4
Quoin Pharmaceuticals' CEO is Michael Myers, appointed in Mar 2018, has a tenure of 6.75 years. total yearly compensation is $1.26M, comprised of 48% salary and 52% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth $22.92K. The average tenure of the management team and the board of directors is 6.8 years and 3.2 years respectively.
Key information
Michael Myers
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 48.0% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.9% |
| Management average tenure | 6.8yrs |
| Board average tenure | 3.2yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$8m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$1m | US$602k | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$2m | US$550k | -US$9m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$1m | US$519k | -US$21m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$579k | US$500k | -US$2m |
Compensation vs Market: Michael's total compensation ($USD1.26M) is above average for companies of similar size in the US market ($USD651.40K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Myers (62 yo)
6.8yrs
Tenure
US$1,255,188
Compensation
Dr. Michael Myers, Ph D., has been an Independent Director at Squarex Pharmaceutical Corp., since November 2022. He serves as Chief Executive Officer and Chairman of Quoin Pharmaceuticals, Ltd.from Octobe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.8yrs | US$1.26m | 0.94% $ 22.9k | |
| Co-Founder | 6.8yrs | US$1.07m | 0.93% $ 22.8k | |
| Chief Financial Officer | 3.1yrs | US$775.94k | 0.57% $ 14.0k |
6.8yrs
Average Tenure
60yo
Average Age
Experienced Management: QNRX's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.2yrs | US$1.26m | 0.94% $ 22.9k | |
| Co-Founder | 3.2yrs | US$1.07m | 0.93% $ 22.8k | |
| Independent Director | 3.2yrs | US$107.62k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$112.62k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$117.62k | 0.0010% $ 25.7 | |
| Independent Director | 3.2yrs | US$122.62k | 0.0063% $ 153.8 | |
| Independent Director | 3.2yrs | US$122.62k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
3.2yrs
Average Tenure
66yo
Average Age
Experienced Board: QNRX's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 08:04 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Quoin Pharmaceuticals, Ltd. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Jason Butler | JMP Securities |
| Jason McCarthy | Maxim Group |